Group 1 - The company, Pioneer Pharmaceuticals (00399), has entered into subscription agreements with two investors, A and B, to issue a total of 90 million shares at a subscription price of HKD 0.312 per share, which represents a discount of approximately 20% compared to the closing price of HKD 0.39 on the date of the agreements [1][2] - The shares subscribed by Investor A will account for approximately 3.00% of the company's existing issued share capital as of the announcement date, while the shares subscribed by Investor B will account for approximately 1.50% [1] - The total gross proceeds from the subscription will be approximately HKD 28.08 million, with a net amount of approximately HKD 27.78 million, intended for general working capital of the group [2] Group 2 - The board of directors believes that the current market conditions present a good opportunity for the company to strengthen its capital base and financial position through the issuance of subscription shares [2] - The issuance of subscription shares is considered an appropriate means to raise additional funds, as the subscription price is lower than the market price, which was reached after fair negotiations with the investors [2]
领航医药生物科技(00399)拟折让约20%发行合共9000万股认购股份